BAX and malignant colon neoplasm: GLTSK (IC50 = 134.6 μM) and GEGSGA (IC50 = 156.7 μM) peptides were able to inhibit colon cancer (HCT-116) cell growth in a dose–response manner, interacted synergistically with oxaliplatin, triggered cell cycle arrest (G2 and G1), and induced apoptosis (32.9% and 23.7%) by causing loss of mitochondrial membrane potential (16.1% and 7.4%), releasing proapoptotic signals (such as Bax), and increasing intracellular ROS concentration, respectively [48].